Tinaa

As NICE NG89 includes day case and chemo as definition of an admission, I ideally want it covered for external reporting and data collection. We dont currently cohort

Thank you everyone, we currently do not have a derogation policy in place for cohorts - does anyone have a policy for cohorts they could share with me please?

For those of you who have the digital capability to collate VTE risk assessment compliance from all patients admitted aged 16 and over, do you include chemotherapy patients? I am having a lot of challenges with the inclusion of this patient cohort Nice is quite clear and states: Admission in the context of this guideline refers to admission as an inpatient, where a bed is provided for 1 or more nights, or admission as a day patient, where a bed is provided for a procedure including surgery or chemotherapy but not for an overnight stay.

For those of you who have the digital capability to collate VTE risk assessment compliance from all patients admitted aged 16 and over, do you include chemotherapy patients? I am having a lot of challenges with the inclusion of this patient cohort Nice is quite clear and states: Admission in the context of this guideline refers to admission as an inpatient, where a bed is provided for 1 or more nights, or admission as a day patient, where a bed is provided for a procedure including surgery or chemotherapy but not for an overnight stay.

We are updating out thromboprophylaxis policy at NGH: We still have a link to COVID-19 thromboprophylaxis, although we don’t routinely do this in practice. The NICE interim rapid guidance for thromboprophylaxis in COVID-19 is still referenced in the NICE thromboprophylaxis policy and so we can’t be seen to be deviating from national policy. Can I ask what the exemplar centres are doing about COVID-19 so we can decide if we should keep this in our policy?